BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 35854762)

  • 1. Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
    Zhao X; Niu J; Shi C; Liu Z
    Reprod Health; 2022 Nov; 19(1):206. PubMed ID: 36333773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of progestin-based combination therapy for endometrial cancer or atypical endometrial hyperplasia: a systematic review and network meta-analysis.
    Cui J; Zhao YC; She LZ; Wang TJ
    Front Oncol; 2024; 14():1391546. PubMed ID: 38764577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin and progestins in women with atypical hyperplasia or endometrial cancer: systematic review and meta-analysis.
    Adamyan L; Pivazyan L; Isaeva S; Shapovalenko R; Zakaryan A
    Arch Gynecol Obstet; 2024 Mar; ():. PubMed ID: 38503850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Case Report of Consecutive Live Birth Twice Through in vitro Fertilization and Embryo Transfer After Endometrial Carcinoma Fertility Preservation Treatment.
    Wang J; Fang Y; Chen T; Xin Z; Wu Y; Yang X
    Int J Womens Health; 2024; 16():395-400. PubMed ID: 38463685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis.
    Shao F; Li Y; Zhao Y
    Front Endocrinol (Lausanne); 2023; 14():1139858. PubMed ID: 37415671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic approaches for the fertility-sparing treatment of endometrial cancer.
    Mitsuhashi A; Shozu M
    J Obstet Gynaecol Res; 2020 Feb; 46(2):215-222. PubMed ID: 32017321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin in Combination with Progesterone Improves the Pregnancy Rate for Patients with Early Endometrial Cancer.
    Yuan F; Hu Y; Han X; Li Q
    Contrast Media Mol Imaging; 2022; 2022():1961016. PubMed ID: 35854762
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
    Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
    Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
    Mitsuhashi A; Kawasaki Y; Hori M; Fujiwara T; Hanaoka H; Shozu M
    BMJ Open; 2020 Feb; 10(2):e035416. PubMed ID: 32114477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin attenuates the production and proliferative effects of prolactin induced by medroxyprogesterone acetate during fertility-sparing treatment for endometrial cancer.
    Gu W; Mitsuhashi A; Kobayashi T; Shozu M
    BMC Cancer; 2022 Jul; 22(1):753. PubMed ID: 35820883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients.
    Mitsuhashi A; Habu Y; Kobayashi T; Kawarai Y; Ishikawa H; Usui H; Shozu M
    J Gynecol Oncol; 2019 Nov; 30(6):e90. PubMed ID: 31576686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curative effects of hysteroscopic resection combined with progesterone on early-stage endometrial cancer and its prognosis.
    Kuang J; Sun S; Xu H; Ni R; Ke F
    J BUON; 2021; 26(4):1320-1326. PubMed ID: 34564987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.
    De Rocco S; Buca D; Oronzii L; Petrillo M; Fanfani F; Nappi L; Liberati M; D'Antonio F; Scambia G; Leombroni M; Dessole M; Lucidi A
    Eur J Obstet Gynecol Reprod Biol; 2022 Jun; 273():90-97. PubMed ID: 35526471
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.